



Psychiatry research at Rho

Smarter psychiatric trials designed and delivered

The Psychiatric Strategy Advantage:

Transforming ambiguity into answers

Nothing about psychiatric research is straightforward. That's because endpoints are subjective. Diagnoses aren't always definitive. Placebo response can derail even the most promising programs.

At Rho, we meet that challenge with psychiatric and regulatory expertise, deep site and rater relationships, and a human-centered approach to data integrity. From major depressive disorder (MDD) to addiction and emerging psychedelic therapies, we bring strategy, experience, and agility to studies that can't afford to get it wrong.

Why **sponsors** choose Rho



Depth where it counts: Sponsors gain a competitive edge from our cross-functional psychiatry team, who optimize protocol strategy and study design to minimize delays and placebo effects.



Feasibility built on trust: We leverage protocol-specific feasibility grounded in historical enrollment data and strategic site input, supported by a robust network of high-performing psychiatric sites.



Crossover strength in neurology: Drawing on our expertise across neurodegenerative and psychiatric conditions, our team bridges the overlap where many psychiatry trials live, delivering protocols that reflect real-world practice so sponsors can manage complexity with confidence.



Placebo response control: Reliable outcomes and confidence in your drug's efficacy begin with minimizing placebo response. We reduce bias and variability through central monitoring, rater and patient training, duplicate subject management, and data integrity safeguards.



Regulatory partnership from day one: Backed by 25+ PhDs in regulatory science and years of psychiatric submission experience, we guide sponsors through evolving regulations without losing momentum.



Strength in stability: Count on Rho for transparent communication, proven startup, and standout study execution, without surprises. Our low employee turnover means your study team stays with you, ensuring trial knowledge stays intact across the life of your study.

Comprehensive **psychiatric trial services**

STUDY PLANNING AND DESIGN

- Protocol optimization to reduce placebo risk and improve eligibility
- Regulatory strategy and pre-IND consultation
- Criteria refinement to balance eligibility with real-world relevance
- Site selection based on proven psychiatric trial experience

STUDY EXECUTION

- Psychiatrist oversight throughout the entire study
- Specialized CRAs trained in psychiatric protocols
- Site and rater training to reduce bias and improve data quality
- Recruitment and feasibility grounded in psych-specific needs

DATA AND SUBMISSION

- Expertise in validated psychiatric scales and assessments
- Early signal detection using RhoViz, our proprietary visualization platform
- Submission-ready packages aligned with global regulatory standards



Meet our **experts**



ANDY FEIGIN, MD

Chief Medical Officer

Andy steers neurological trials with scientific rigor and real-world foresight. With 30+ years as a neurologist, he's led global, multi-center programs, and first in-human-trials—including the first gene therapy trial for Parkinson's. From protocol design to regulatory engagement, Andy knows where trials succeed and where they stall. His decades at the forefront of neurodegenerative research give sponsors a partner who cuts through complexity and builds studies that stand up to scrutiny.



BRETT GORDON

Vice President, Project Delivery

With 25+ years of industry experience, Brett has seen just about everything in clinical development. He balances big-picture thinking with project-level precision and strong relationships. Through operational strategy and executive level oversight, Brett supports teams to ensure high-quality and timely program delivery. While he has background in CNS and pain, ADHD is where he's left his mark—overseeing trial programs for at least five compounds. Brett understands that clinical research can get complicated, but he makes it feel doable.



CANDICE FRENCH

Director, Project Delivery

With 14 years of CNS trial leadership, Candice guides psychiatric and neurological studies toward stronger outcomes, delivering clarity where others see complexity. Sponsors rely on her ability to anticipate and navigate operational challenges—from minimizing placebo response to ensuring patient retention and compliance. Her expertise in cognitive and neuropsych assessments enables her to equip sites, reduce variability, and deliver cleaner, more reliable data that supports confident decision-making.

Complex doesn't mean **chaotic**

Build your next psychiatric study with the attention it deserves. **Let's get started.**



CONTACT US

To learn more, visit us at: rhoworld.com